Oxaliplatin In Operable Colorectal CancerA Viewpoint by Gérard Milano

被引：0
|
作者：
Gérard Milano
机构：
[1] Centre Antoine Lacassagne,Oncopharmacology Unit
来源：
Drugs | 2005年 / 65卷
关键词：
Vascular Endothelial Growth Factor; Epidermal Growth Factor Receptor; Irinotecan; Oxaliplatin; Leucovorin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 97
相关论文
共 33 条
  • [21] Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)
    Valencak, J
    Lathan, B
    Kornek, G
    Raderer, M
    Klein, G
    Hejna, M
    Brodovic, T
    Weinländer, G
    Depisch, D
    Scheithauer, W
    BRITISH JOURNAL OF CANCER, 1998, 78 : 36 - 36
  • [22] Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)
    Scheithauer, W
    Lathan, B
    Kornek, G
    Raderer, M
    Valencak, J
    Klein, G
    Hejna, M
    Brodovic, T
    Weinlander, G
    Depisch, D
    ANNALS OF ONCOLOGY, 1998, 9 : 172 - 172
  • [23] Association of SLC22A2 c.808T>G (rs316019) in the occurrence of hematological toxicity of Oxaliplatin in patients with colorectal cancer
    Dimitrov, Dimitar
    Ivanov, Hristo
    Miteva-Marcheva, Nelly
    Raycheva, Gabriela
    Grudeva, Zhanet
    Popov, Veselin
    Linev, Aleksandar
    Zheliaskov, Ivan
    Topalov, Momchil
    Stoyanova, Vili
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 307 - 307
  • [24] Difference in Overall Survival in Colorectal Cancer Patients With the KRas P.G13D and Other KRas Mutations After the Failure of 5-fluorouracil, Oxaliplatin, and Irinotecan
    Suyama, K.
    Yoshino, T.
    Kawamoto, Y.
    Bando, H.
    Doi, T.
    Baba, H.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S424 - S425
  • [25] A PDX model combined with CD-DST assay to evaluate the antitumor properties of KRpep-2d and oxaliplatin in KRAS (G12D) mutant colorectal cancer
    Li, Wuguo
    Chen, Wei
    Wang, Jialin
    Zhao, Guangyin
    Chen, Lianzhou
    Wan, Yong
    Luo, Qianxin
    Li, Wenwen
    Huang, Haoji
    Li, Wenying
    Li, Wu
    Yang, Yutong
    Chen, Daici
    Su, Qiao
    HELIYON, 2022, 8 (12)
  • [26] HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/ Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
    Garziera, Marica
    Virdone, Saverio
    De Mattia, Elena
    Scarabel, Lucia
    Cecchin, Erika
    Polesel, Jerry
    D'Andrea, Mario
    Pella, Nicoletta
    Buonadonna, Angela
    Favaretto, Adolfo
    Toffoli, Giuseppe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [27] Irinotecan is superior to oxaliplatin in KRAS-G12C-mutated (K-G12C-m) colorectal cancer (CRC) and should be preferred in combination strategies with K-G12C inhibitors. A multicenter propensity score-matched (PSM) retrospective analysis
    Morelli, C.
    Lucchetti, J.
    Calegari, M. A.
    Rofei, M.
    Guerriero, S.
    Riondino, S.
    Flaminio, V.
    Parisi, G.
    Lo Prinzi, F.
    Trovato, G.
    Vincenzi, B.
    Salvatore, L.
    Roselli, M.
    Formica, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S705 - S705
  • [28] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [29] Neural precursor cell expressed, developmentally downregulated 8-activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis
    Zheng, Wanwei
    Luo, Zhongguang
    Zhang, Jun
    Min, Pei
    Li, Wenshuai
    Xu, Diannan
    Zhang, Ziqiang
    Xiong, Panpan
    Liang, Hong
    Liu, Jie
    MOLECULAR MEDICINE REPORTS, 2017, 15 (05) : 2795 - 2801
  • [30] Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by Gruppo Oncologico Nord-Ovest (G. O. N. O.)
    Bursi, Simona
    Masi, Gianluca
    Antonuzzo, Andrea
    Loupakis, Fotios
    Barbara, Cecilia
    Barletta, Maria
    Allegrini, Giacomo
    Pfanner, Elisabetta
    Murr, Rita
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2006, 17 : 121 - 121
1234